PTC Therapeutics director Schmertzler sells $1.35m shares

PTC Therapeutics director Michael Schmertzler sold 20,000 shares of the company's common stock on September 16 and 17, 2026, amounting to roughly $1.35 million. The transactions took place in multiple trades over two days, with prices fluctuating between $66.58 and $68.45 per share. On September 16, Schmertzler sold 2,994 shares at a weighted average price of $66.58, followed by an additional 7,006 shares on the same day at a weighted average price of $67.35.

On September 17, he continued the sales with 9,624 shares at a weighted average price of $67.83, and concluded with a final transaction of 376 shares at a weighted average price of $68.45. These actions were carried out in accordance with a Rule 10b5-1 trading plan established by Section Six Partners, L.P. on May 14, 2026. Schmertzler, a general and limited partner of the partnership, disclosed his indirect beneficial ownership of 1,296,594 shares of PTC Therapeutics common stock through Section Six Partners.

In other news, PTC Therapeutics reported strong second-quarter 2026 results, surpassing market expectations with earnings of $0.92 per share and revenue of $361 million. The company's robust performance and financial health, coupled with a surge in global biotech funding, suggest a positive outlook for the biotech sector.